CTLA4 and melanoma: High levels of MDSCs in patients with nonresectable melanoma negatively correlate with the clinical response to ipilimumab (anti–CTLA-4) (33, –35), and predicts failure of second-line immunotherapy with anti–PD-1 (nivolumab) (36).